MedTrace Logo

Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations

NCT00134342 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2010-12-23

No results posted yet for this study

Summary

The tuberculin skin test (TST) has been the gold standard for diagnosing latent tuberculosis for almost 100 years. While this test performs reasonably well in healthy, non-bacille Calmette-Guerin (BCG) vaccinated populations, it is believed to perform less well in patients who do not have intact cellular immune systems (immunocompromised).

The investigators hypothesize that a new test, the T-SPOT TB ELISPOT test will provide a more accurate measurement of latent infection in immunocompromised people. This study will compare the TST to the T-SPOT TB ELISPOT test, and to the results of an expert physician diagnostic panel.

Conditions

Interventions

OTHER

T-SPOT TB ELISPOT test

ELISPOT test for detecting T cell responses to tuberculosis antigens.

Sponsors & Collaborators

  • Oxford Immunotec

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Michael Gardam, MD · University Health Network, University of Toronto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00134342 on ClinicalTrials.gov